CA2576135C - Noyau de comprime polymere par compression directe - Google Patents

Noyau de comprime polymere par compression directe Download PDF

Info

Publication number: CA2576135C
Authority: CA; Canada
Prior art keywords: coating; core; weight; allylamine; tablet
Prior art date: 1999-10-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2576135A

Other languages

English (en)

Other versions

CA2576135A1 (fr

Inventor

Joseph Tyler

John S. Petersen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genzyme Corp

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-19

Filing date

2000-10-13

Publication date

2011-12-06

2000-10-13 Application filed by Genzyme Corp filed Critical Genzyme Corp

2000-10-13 Priority claimed from CA002387915A external-priority patent/CA2387915C/fr

2001-04-26 Publication of CA2576135A1 publication Critical patent/CA2576135A1/fr

2011-12-06 Application granted granted Critical

2011-12-06 Publication of CA2576135C publication Critical patent/CA2576135C/fr

2020-10-13 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229920000642 polymer Polymers 0.000 title claims description 42
238000007907 direct compression Methods 0.000 title description 4
229920000083 poly(allylamine) Polymers 0.000 claims abstract description 18
239000007891 compressed tablet Substances 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 8
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims abstract 2
238000000576 coating method Methods 0.000 claims description 37
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 36
239000011248 coating agent Substances 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 28
KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 claims description 26
229960003027 sevelamer hydrochloride Drugs 0.000 claims description 26
-1 poly(allylamine) Polymers 0.000 claims description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
235000021355 Stearic acid Nutrition 0.000 claims description 8
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
239000008117 stearic acid Substances 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 7
201000005991 hyperphosphatemia Diseases 0.000 claims description 6
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
229920002518 Polyallylamine hydrochloride Polymers 0.000 claims description 2
239000004971 Cross linker Substances 0.000 claims 2
125000006686 (C1-C24) alkyl group Chemical group 0.000 claims 1
239000004014 plasticizer Substances 0.000 claims 1
239000000377 silicon dioxide Substances 0.000 claims 1
235000012239 silicon dioxide Nutrition 0.000 claims 1
239000002253 acid Substances 0.000 abstract description 5
239000013543 active substance Substances 0.000 abstract description 4
239000003826 tablet Substances 0.000 description 83
239000000463 material Substances 0.000 description 16
239000004480 active ingredient Substances 0.000 description 11
238000000034 method Methods 0.000 description 10
229940075614 colloidal silicon dioxide Drugs 0.000 description 9
239000011347 resin Substances 0.000 description 9
229920005989 resin Polymers 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000008199 coating composition Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 5
239000002952 polymeric resin Substances 0.000 description 5
229920003002 synthetic resin Polymers 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
229960003693 sevelamer Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000003529 anticholesteremic agent Substances 0.000 description 2
229940127226 anticholesterol agent Drugs 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
238000001035 drying Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000000887 hydrating effect Effects 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002547 new drug Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000009492 tablet coating Methods 0.000 description 2
239000002700 tablet coating Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004848 polyfunctional curative Substances 0.000 description 1
229940020428 renagel Drugs 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
230000009182 swimming Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000012463 white pigment Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2576135A 1999-10-19 2000-10-13 Noyau de comprime polymere par compression directe Expired - Fee Related CA2576135C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US16025899P	1999-10-19	1999-10-19
US60/160,258		1999-10-19
US17422700P	2000-01-03	2000-01-03
US60/174,227		2000-01-03
CA002387915A CA2387915C (fr)	1999-10-19	2000-10-13	Noyau de comprime polymere par compression directe

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002387915A Division CA2387915C (fr)	1999-10-19	2000-10-13	Noyau de comprime polymere par compression directe

Publications (2)

Publication Number	Publication Date
CA2576135A1 CA2576135A1 (fr)	2001-04-26
CA2576135C true CA2576135C (fr)	2011-12-06

Family

ID=37890087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2576135A Expired - Fee Related CA2576135C (fr)	1999-10-19	2000-10-13	Noyau de comprime polymere par compression directe

Country Status (1)

Country	Link
CA (1)	CA2576135C (fr)

2000
- 2000-10-13 CA CA2576135A patent/CA2576135C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2576135A1 (fr)	2001-04-26

Legal Events

Date	Code	Title	Description
2007-02-15	EEER	Examination request
2019-11-26	MKLA	Lapsed	Effective date: 20191015

Publication	Publication Date	Title
US9931358B2 (en)	2018-04-03	Direct compression polymer tablet core
EP1239837B1 (fr)	2005-01-05	Noyau de comprime polymere par compression directe
US20120321711A1 (en)	2012-12-20	Direct compression polymer tablet core
KR100456202B1 (ko)	2004-11-09	인산 결합성 중합체 제제
EP2490675B1 (fr)	2019-01-23	Composition pharmaceutique comprenant sevelamer
US20100166861A1 (en)	2010-07-01	Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
CA2576135C (fr)	2011-12-06	Noyau de comprime polymere par compression directe